Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Current Leases: 2019-2024

Historic Current Leases for Tg Therapeutics (TGTX) over the last 6 years, with Dec 2024 value amounting to $1.2 million.

  • Tg Therapeutics' Current Leases fell 13.24% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 13.24%. This contributed to the annual value of $1.2 million for FY2024, which is 19.99% down from last year.
  • Tg Therapeutics' Current Leases amounted to $1.2 million in FY2024, which was down 19.99% from $1.4 million recorded in FY2023.
  • Tg Therapeutics' Current Leases' 5-year high stood at $1.7 million during FY2020, with a 5-year trough of $1.2 million in FY2024.
  • Over the past 3 years, Tg Therapeutics' median Current Leases value was $1.4 million (recorded in 2023), while the average stood at $1.4 million.
  • Per our database at Business Quant, Tg Therapeutics' Current Leases rose by 10.02% in 2022 and then fell by 19.99% in 2024.
  • Over the past 5 years, Tg Therapeutics' Current Leases (Yearly) stood at $1.7 million in 2020, then fell by 13.90% to $1.4 million in 2021, then climbed by 10.02% to $1.6 million in 2022, then dropped by 8.54% to $1.4 million in 2023, then declined by 19.99% to $1.2 million in 2024.